RxDoctor Payments Data

Olga Voroshilovsky, MD

Clinical Cardiac Electrophysiology · West Hollywood, CANPI 1659402311

Payments from drug & device makers

$8,339in general payments, 2019–2025

Across 142 payments — averaging $58.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Abbott$3K
  • Novartis$308
  • Pfizer$88
  • Amgen$82
  • Edwards Lifesciences$74
  • plus $383 from 10 others

What the payments were for

  • Travel & lodging$7038%
  • Food & beverage$7,63692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,339 in reported general payments places this provider in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$348,024
Medicare patients
303
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$171,369
Repatha SureclickEvolocumab44$36,341
MounjaroTirzepatide15$19,565
FarxigaDapagliflozin Propanediol17$13,719
XareltoRivaroxaban15$10,556
VascepaIcosapent Ethyl18$6,046
Amiodarone Hcl100$5,671
Metoprolol Succinate251$4,753
EdarbiAzilsartan Medoxomil21$4,646
Rosuvastatin Calcium162$3,175
Nebivolol Hcl41$2,658
Telmisartan48$1,928
Olmesartan Medoxomil38$666
Amlodipine Besylate76$644
Atorvastatin Calcium52$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$171,369216 claims
Lilly USA, LLCMounjaro$42$19,56515 claims
AstraZenecaFarxiga$41$13,71917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →